Tags

Type your tag names separated by a space and hit enter

Vaccines for COVID-19: Where do we stand in 2021?
Paediatr Respir Rev. 2021 Sep; 39:22-31.PR

Abstract

As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity.

Authors+Show Affiliations

National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases, Nepean Hospital, Penrith, NSW, Australia.National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, NSW, Australia. Electronic address: Philip.Britton@health.nsw.gov.au.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34362666

Citation

Sharma, Ketaki, et al. "Vaccines for COVID-19: Where Do We Stand in 2021?" Paediatric Respiratory Reviews, vol. 39, 2021, pp. 22-31.
Sharma K, Koirala A, Nicolopoulos K, et al. Vaccines for COVID-19: Where do we stand in 2021? Paediatr Respir Rev. 2021;39:22-31.
Sharma, K., Koirala, A., Nicolopoulos, K., Chiu, C., Wood, N., & Britton, P. N. (2021). Vaccines for COVID-19: Where do we stand in 2021? Paediatric Respiratory Reviews, 39, 22-31. https://doi.org/10.1016/j.prrv.2021.07.001
Sharma K, et al. Vaccines for COVID-19: Where Do We Stand in 2021. Paediatr Respir Rev. 2021;39:22-31. PubMed PMID: 34362666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vaccines for COVID-19: Where do we stand in 2021? AU - Sharma,Ketaki, AU - Koirala,Archana, AU - Nicolopoulos,Katrina, AU - Chiu,Clayton, AU - Wood,Nicholas, AU - Britton,Philip N, Y1 - 2021/07/12/ PY - 2021/07/06/received PY - 2021/07/06/accepted PY - 2021/8/8/pubmed PY - 2021/9/24/medline PY - 2021/8/7/entrez KW - COVID-19 KW - COVID-19 vaccines KW - SARS-CoV-2 KW - Vaccines SP - 22 EP - 31 JF - Paediatric respiratory reviews JO - Paediatr Respir Rev VL - 39 N2 - As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. SN - 1526-0550 UR - https://www.unboundmedicine.com/medline/citation/34362666/Vaccines_for_COVID_19:_Where_do_we_stand_in_2021 L2 - https://linkinghub.elsevier.com/retrieve/pii/S1526-0542(21)00065-8 DB - PRIME DP - Unbound Medicine ER -